Data / Form D filings / Transition Bio, Inc.
Transition Bio, Inc.: Form D filings
Transition Bio, Inc., a biotechnology company in Cambridge, MA, filed 4 Form D notices with the SEC between 2022 and 2024. The latest, on October 25, 2024, reports $13.3 million sold of a $21.3 million offering to 8 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- ONE MIFFLIN PLACE, SUITE 400, Cambridge, MA, 02138
- Phone
- (917) 445-5573
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2020
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1920890
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 25, 2024 | New notice | $21,265,426 | $13,265,426 | $8,000,000 | 8 | Oct 11, 2024 | sec.gov |
| Jan 10, 2024 | New notice | $15,000,000 | $6,000,000 | $9,000,000 | 5 | Dec 22, 2023 | sec.gov |
| Mar 7, 2023 | Amendment | $50,000,000 | $39,086,000 | $10,914,000 | 22 | Mar 24, 2022 | sec.gov |
| Apr 8, 2022 | New notice | $30,555,975 | $30,555,975 | 23 | Mar 24, 2022 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Tuomas Knowles | Director | |
| Kathy Yi | Director | |
| Robert Weeks | Director | |
| George Martin | Executive Officer, Director | |
| Al Sandrock | Director | |
| Stephanie Torruella | Executive Officer | |
| Samuel Cohen | Director | |
| Preet Makkar | Executive Officer | |
| Paxton Major | Director |
Other biotechnology companies in Massachusetts that filed recently
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
Every Form D from the week of Oct 21, 2024 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Transition Bio, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.